The current trend of using Glasgow Coma Scale (GCS) as a standard procedure to provide a prognostic scale for Traumatic Brain Injury (TBI) has become limited since patients are usually under the influence of sedatives to keep them calm. Assessing GCS by the time they arrive at the trauma unit will not be indicative of the actual conscious state. There are also possibilities of missing TBI as patients can appear to be normal with full GCS scores while neuroimaging tests such as CT or MRI scans may or may not show evidence of any damage. This technology refers to a unique method that is able to distinguish and grade the severity of Traumatic Brain Injury (TBI) by identifying the concentration levels of specific serum biomarkers associated with brain injury.
This technology refers to a unique method that is able to distinguish and grade the severity of Traumatic Brain Injury (TBI) by identifying the concentration levels of specific serum biomarkers associated with brain injury. Current clinical assessment for TBI may not be accurate and can be compromised by many factors (e.g. Alcohol intoxication, hypotension, sedatives etc). Furthermore, there is no available biochemical test to distinguish the severity of the TBI apart from clinical assessment. This invention is able to fill that void by not just determining if TBI has occurred but also the severity of it. As such, it has tremendous market potential in the medical field, especially for hospitals and emergency centres. Benefits include being able to detect TBI and to assess the severity of it. An accurate appreciation of the severity of TBI can help to predict outcomes and rationally help to decide when the application of aggressive therapeutic interventions would be necessary.
Traumatic Brain Injury (TBI) can be masked by various factors such as sedatives, facial injuries, alcohol consumption and low blood oxygen among others. However, biological components responding to TBI are unaffected by these factors. Therefore, using said components as biological markers allow for the diagnosis of TBI which would be otherwise impossible. It is also minimally invasive as only blood from the patient will be utilised. Biological components also react in a consistent pattern to trauma. By assessing the increase in these markers, this innovation can assist in the determination of the severity of TBI.